LY3526318 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Low-back Pain
Conditions
Chronic Low-back Pain
Trial Timeline
Oct 25, 2021 → Jun 17, 2022
NCT ID
NCT05086289About LY3526318 + Placebo
LY3526318 + Placebo is a phase 2 stage product being developed by Eli Lilly for Chronic Low-back Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT05086289. Target conditions include Chronic Low-back Pain.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05177094 | Phase 2 | Completed |
| NCT05086289 | Phase 2 | Completed |
| NCT05080660 | Phase 2 | Completed |
| NCT04682119 | Phase 1 | Completed |
| NCT04183283 | Phase 1 | Completed |
| NCT03977974 | Phase 1 | Terminated |
Competing Products
20 competing products in Chronic Low-back Pain